1-3 of 3
Huyuan Yang, PhD
Close
Sort by
Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-134039
Published: 2020
Journal Articles

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta, PhD, Michael J Hanley, PhD, R. Donald Harvey, PharmD, Ashraf Z Badros, MD, Brea C. Lipe, MD, Vishal Kukreti, Jesus G. Berdeja, MD, Huyuan Yang, PhD, Ai-Min Hui, MD PhD, Xiaoquan Zhang, MD PhD, Karthik Venkatakrishnan, PhD, Ajai Chari, MD
Journal: Blood
Blood (2015) 126 (23): 4227.
https://doi.org/10.1182/blood.V126.23.4227.4227
Published: 2015
Journal Articles

A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment

Neeraj Gupta, PhD, Michael J Hanley, PhD, Karthik Venkatakrishnan, PhD, Raymond Perez, MD, Robin E Norris, MD, John Nemunaitis, MD, Huyuan Yang, PhD, Gerald Falchook, MD, Richard Labotka, MD MS, Siqing Fu, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3032.
https://doi.org/10.1182/blood.V126.23.3032.3032
Published: 2015